NCT05430971 Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry
| NCT ID | NCT05430971 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Immune Oncology Research Institute |
| Condition | Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2022-07-01 |
| Primary Completion | 2032-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2022-07-01 with a primary completion date of 2032-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is a very rare hematologic malignancy. Despite recent advances, at present there is no consensus on the optimal treatment of BPDCN. The optimal therapy of disease remains to be determined, and due to the rarity of cases, there is a need for international collaboration to collect data on BPDCN clinical presentations, diagnostics, treatment regimens and outcomes. Therefore, the objectives of this study are: (1) to build a large database of patients with BPDCN, (2) to investigate the characteristics and outcome of the disease with different treatment regimens, (3) to evaluate prognostic factors, and (4) to generate data-based prospective treatment recommendations.
Eligibility Criteria
Inclusion Criteria: * Diagnosis of BPDCN * Signed informed consent form for prospective patients Exclusion Criteria: \-
Contact & Investigator
Astghik Voskanyan, MD
PRINCIPAL INVESTIGATOR
Immune Oncology Research Institute, Yerevan, Armenia
Frequently Asked Questions
Who can join the NCT05430971 clinical trial?
This trial is open to participants of all sexes, studying Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05430971 currently recruiting?
Yes, NCT05430971 is actively recruiting participants. Contact the research team at astghikvos@gmail.com for enrollment information.
Where is the NCT05430971 trial being conducted?
This trial is being conducted at Miami, United States, Tampa, United States, Seattle, United States, Yerevan, Armenia and 11 additional locations.
Who is sponsoring the NCT05430971 clinical trial?
NCT05430971 is sponsored by Immune Oncology Research Institute. The principal investigator is Astghik Voskanyan, MD at Immune Oncology Research Institute, Yerevan, Armenia. The trial plans to enroll 200 participants.